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Abstract
We have previously demonstrated that the replacement of the S gene from an avirulent strain (Beaudette) of infectious
bronchitis virus (IBV) with an S gene from a virulent strain (M41) resulted in a recombinant virus (BeauR-M41(S)) with the in
vitro cell tropism of the virulent virus but that was still avirulent. In order to investigate whether any of the other structural
or accessory genes played a role in pathogenicity we have now replaced these from the Beaudette strain with those from
M41. The recombinant IBV was in effect a chimaeric virus with the replicase gene derived from Beaudette and the rest of the
genome from M41. This demonstrated that it is possible to exchange a large region of the IBV genome, approximately
8.4 kb, using our transient dominant selection method. Recovery of a viable recombinant IBV also demonstrated that it is
possible to interchange a complete replicase gene as we had in effect replaced the M41 replicase gene with the Beaudette
derived gene. Analysis of the chimaeric virus showed that it was avirulent indicating that none of the structural or accessory
genes derived from a virulent isolate of IBV were able to restore virulence and that therefore, the loss of virulence associated
with the Beaudette strain resides in the replicase gene.
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Introduction
Avian infectious bronchitis virus (IBV) is a member of the genus
Coronavirus, family Coronaviridae, order Nidovirales [1,2]. Together
with the genetically closely related Turkey coronavirus [3–6],
Pheasant coronavirus [7], and recently identified coronaviruses
from several species of wild birds [8,9], a beluga whale [10] and an
Asian Leopard cat [11] form the Group 3 coronaviruses. IBV is a
highly infectious pathogen of domestic fowl that replicates
primarily in the respiratory tract but also in epithelial cells of
other organs, including the gut, kidney and oviduct [12–14], and is
the causative agent of infectious bronchitis, a disease that is
responsible for economic losses in the poultry industry throughout
the world [15].
Coronaviruses are enveloped viruses that replicate in the cell
cytoplasm and contain a single-stranded, positive-sense RNA
genome of 28 to 32 kb [16]. IBV has a 27.6 kb RNA genome and
like all coronaviruses contains the four structural proteins; spike
glycoprotein (S), small membrane protein (E), integral membrane
protein (M) and nucleocapsid protein (N) which interacts with the
genomic RNA. All coronaviruses also encode a set of accessory
protein genes of unknown function that are not required for
replication in vitro [17–23], but may play a role in pathogenesis
[19,22]. IBV encodes two accessory genes, genes 3 and 5, which
both express two accessory proteins 3a, 3b and 5a, 5b,
respectively. In addition to the structural and accessory genes,
two-thirds of a coronavirus genome comprises the replicase gene,
which expresses two polyproteins, pp1a and pp1ab, in which
pp1ab is an extension product of pp1a as a result of a -1 ribosomal
shift mechanism. The two polyproteins are cleaved by two types of
virus-encoded proteinases usually resulting in 16 non-structural
proteins (Nsp1-16); IBV lacks Nsp1 thereby encoding Nsp2-16.
We have previously shown that the IBV accessory genes are not
required for replication in vitro [17,18]; however, we could not
determine any role of the IBV accessory proteins in pathogenicity
as our reverse genetics system is based on the avirulent Beaudette
strain. Replacement of the Beaudette S gene with the correspond-
ing M41 S gene sequence altered the tropism of the rIBV but did
not result in a change in virulence [24–26]. This implied that
although the IBV S gene may play a role in virulence, associated
with tropism, expression of an S gene from a virulent strain alone
was not sufficient to alter the avirulent phenotype associated with
Beaudette.
Infectious bronchitis is mainly controlled by the use of live
attenuated vaccines derived from virulent viruses by multiple serial
passages, usually greater than 50 passages, in 10-11-day-old
embryonated chicken eggs [13,27–29]. As a consequence of this
process the virus becomes more adapted for the embryo, reflected by
more efficient replication and higher pathogenicity for the embryo,
with concomitant attenuation for chickens and in some cases loss of
immunogenicity. However, the mutations associated with attenuation
of pathogenicity for the chicken are unknown and variable leading to
differing efficacies associated with different vaccines.
Our previous studies have shown that replacement of the S gene
from the avirulent Beaudette isolate with that from a virulent virus
(M41) did not restore virulence but did alter the tropism of the
rIBV and restore immunogenicity for subsequent challenge with
M41. Previously Beaudette had been considered to be poorly
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study, we describe the generation of recombinant IBVs that
consisted of the replicase gene from the avirulent Beaudette strain
and the structural and accessory genes from the virulent M41
isolate of IBV, to determine whether the replicase or the
combination of the structural and accessory genes of IBV play a
role in pathogenesis.
Materials and Methods
Cells and viruses
The growth of IBV in chick kidney (CK) cells was as described
previously [31–33]. The IBV isolates used were: (1) Beaudette-CK
(Beau-CK; [34]), a virus adapted for growth in CK cells that can
grow on but has not been adapted for growth in Vero cells, an
African green monkey cell line; (2) Beau-R, a recombinant IBV
(rIBV) produced from a full-length cDNA of Beau-CK using our
IBV reverse genetics system [35]; and (3) M41-CK, an isolate
derived from M41 [36] following adaption to growth on CK cells.
Both the Beaudette and M41 strains of IBV belong to the same,
Massachusetts, serotype. All IBV strains were titrated in CK cells.
Vaccinia viruses were grown and titrated on Vero cells and large
stocks for DNA isolation were grown in BHK-21 cells [37]. All
nucleotide and amino acid residue numbers refer to the positions
in IBV Beau-R [35] accession N
o AJ311317.
Construction of modified IBV cDNA
The region of the IBV M41 genome corresponding to the
structural, accessory genes and the 39-UTR was ligated onto the
last 1416 nt of the Beau-R replicase gene and inserted into HindIII
and SalI digested pGPT-NEB193 [25]. The resulting plasmid,
pGPT-BeauR-Rep-M41-Struct-3UTR, consisted of the 39-end of
the replicase gene of Beau-R, and the region of the M41-CK
genome encoding the structural and accessory genes terminated by
the M41-CK derived 39UTR (Fig. 1).
Generation of recombinant vaccinia viruses containing
modified IBV cDNAs
The IBV cDNA within pGPT-BeauR-Rep-M41-Struct-3UTR was
introduced, by homologous recombination using the transient
dominant selection (TDS) ([25,37]), into the IBV Beaudette cDNA
within the vaccinia virus genome in rVV-BeauR-Rep-DStruct
containing Beau-R-derived sequence corresponding to the replicase
gene followed by the first 376 nt of the S gene, part of the N gene and
the 39-UTR (Fig. 1). Briefly, 50% confluent monolayers of vero cells
were infected with rVV-BeauR-Rep-DStruct, containing the Beau-R
cDNA sequence, at a MOI of 0.2 and transfected 2 h later with 5 mgo f
pGPT-BeauR-Rep-M41-Struct-3UTR in lipofectin (Invitrogen). Re-
sultant phenotypically GPT
+ rVVs were selected by three rounds of
plaque purification using vero cells in the presence of 25 mg/ml
mycophenolic acid (MPA), 250 mg/ml xanthine and 15 mg/ml
hypoxanthine. Randomly selected MPA resistant rVVs were grown
and plaque purified three times using vero cells in the absence of
selection medium. This resulted in a second recombination event (see
Fig. 1) involving the loss of the GPT gene from the rVVs, and either
generation of an IBV cDNA corresponding to the sequence in rVV-
BeauR-Rep-DStruct or a full-length IBV cDNA consisting of a Beau-R
replicase gene and the rest of the IBV genome derived from IBV M41-
CK within the VV genome (Fig. 1). PCR was used to confirm the
absence of the GPT gene in resulting rVVs, which were further
screened by PCR amplification of the IBV 39-UTR, using
oligonucleotides BG56 (59-
26941CAACAGCGCCCAAAGAAG
26958)
and 93/100 (59-
27607GCTCTAACTCTATACTAGCCT
27587-39),
part of the replicase gene, using oligonucleotides BG40 (59-
18941ATC-
TAATTTGCTCGTTCA
18958-39 and BG128 (59-
19720CGCCAC-
TCCTTTGTCGCTTC
19739-39, and the junction of the replicase and
S genes using oligonucleotides BG40 (59-
18941ATCTAATT-
TGCTCGTTCA
18958-39 and BG134 (59-
21398AGCAATT-
GAAACTGAAAGTG
21417-39. Oligonucleotides BG-56 and 93/100
were used to discriminate between the 39-UTRs from Beau-R and
M41 derived sequences; the 39-UTR from Beau-R results in a 667 bp
product but a 483 bp PCR from M41-CK, due to a 184 nt deletion in
the M41 39-UTR. A rVV, rVV-BeauR-Rep-M41-Struct, that
contained a full-length IBV cDNA consisting of the replicase gene
from Beau-R and the rest of the genome derived from IBV M41-CK
was identified and used for further work.
Recovery of infectious IBV
Recombinant vaccinia virus DNA from rVV-BeauR-Rep-M41-
Struct containing the BeauR-Rep-M41-Struct chimaeric full-
length IBV cDNA was purified and used for the rescue of rIBVs
in CK cells using rFPV/T7 [38] for the generation of infectious
IBV RNA ([25,35,37]). Resultant chimaeric rIBVs were passed
three times in CK cells before being used in subsequent
experiments. Total cellular RNA was extracted from IBV-infected
CK cells using the RNeasy method (Qiagen) and RT-PCR
(Ready-To-Go
TM RT-PCR beads) for amplification of the 39-
UTR of the rIBV-derived RNA, using oligonucleotides BG 56 and
93/100, to confirm the identity of the rIBV.
Multiple-step growth curves of rIBVs in CK cells
Confluent monolayers of CK cells in 6-well plates were infected
with viruses at a MOI of 0.1 PFU in triplicate for each time point.
Following attachment, for 1 h at 37uC, the cells were washed twice
with phosphate-buffered saline (PBS) to remove residual virus and
incubated at 37uC. Samples of media were collected at 24, 48, 72
and 96 h post-infection and assayed in triplicate for progeny virus
by plaque assay using CK cells.
Growth kinetics of rIBVs in tracheal organ cultures
Chicken tracheal organ cultures (TOCs) were prepared from
19-day-old specific pathogen free (SPF) Rhode Island Red chicken
embryos [39]. Groups of five TOCs, in triplicate, were inoculated
with 0.5 ml of medium containing 5.4610
4 PFU/ml of each virus.
After incubation at 37uC for 1 h, the inoculum was removed and
the TOCs were washed three times with PBS, 1 ml of medium was
added and the TOCs were incubated at 37uC until the samples
were taken. At the selected time points medium from the TOCs
was removed and analysed for progeny virus by plaque titration on
CK cells.
In vivo analysis of the rIBVs
All experiments were carried out in accordance with the UK
Home Office guidelines using SPF Rhode Island Red chickens
obtained from the Poultry Production Unit of the Institute for
Animal health. Four groups (n=12) of 1-day-old SPF Rhode
Island Red chickens were inoculated via the conjunctival (eye
drop) and intranasal routes with 10
6 PFU/ml of each virus in a
total of 0.1 ml serum-free BES (N,N-Bis(2-hydroxyethyl)-2-
aminoethanesulphonic acid) medium. The chickens were housed
in positive-pressure, HEPA-filtered isolation rooms, and each
group was housed in a separate room. The birds in the mock-
infected group were inoculated with serum-free BES medium.
Assessment of pathogenicity
The IBV-associated clinical signs used to determine pathoge-
nicity were snicking, tracheal rales (a sound emanating from the
IBV Replicase in Pathogenicity
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wheezing (dyspoena), nasal discharge, watery eyes and ciliary
activity of the trachea [26]. Chicks were observed daily for clinical
signs; snicks (a sound similar to a sneeze) were counted by two
persons over 2 minutes. Birds were checked individually for the
presence of tracheal rales, nasal discharge, watery eyes and
wheezing. Tracheas were removed from three randomly selected
chickens from each group at 4 and 7 days post-inoculation for
assessment of ciliary activity. Ten 1 mm sections were cut from
three different regions of each trachea and the level of ciliostasis of
each tracheal section was determined.
Virus replication in chickens
The remaining regions of the tracheas from the infected birds
were cut longitudinally and the epithelial cells scraped from the
tracheas and transferred to 1 ml PBS. The samples were analysed
for the presence of viable IBV by titration in TOCs or used for
RNA extraction using the RNeasy method and analysed by RT-
Figure 1. The transient dominant selection process for modifying the truncated Beau-R cDNA within vaccinia virus rVV-BeauR-Rep-
D-Struct. The M41-CK-derived cDNA, representing the M41 structural and accessory genes and the M41 39-UTR, within pGPT-BeauR-Rep-M41-Struct-
3UTR was fused to the Beau-R replicase gene in the rVV by a homologous recombination event between the Beau-R replicase sequence common to
both constructs. A potential rVV, rVV-BeauR-Rep-M41-Struct, containing a full-length IBV cDNA with the replicase gene from Beau-R and the rest of
the genome from M41-CK was isolated following the TDS process. The complete plasmid DNA was fused to the truncated Beau-R cDNA by a single-
step homologous recombination event; via the Beau-R replicase sequence common to both sequences. The initial resultant rVVs had a GPT
+
phenotype allowing selection in the presence of mycophenolic acid. Removal of mycophenolic acid resulted in two types of spontaneous
intramolecular recombination events, due to the instability of the IBV cDNA with tandem repeats of similar sequences, resulting in either rVV-BeauR-
Rep-D-Struct (no modification) or in rVV-BeauR-Rep-M41-Struct; the desired rVV. Both recombination events resulted in the loss of the GPT gene. The
IBV genes representing the structural and accessory genes are shown along with the 39-UTRs and IGR sequences, a potential recombination event is
indicated between the 1416 nt of the Beau-R replicase gene sequence common to both constructs.
doi:10.1371/journal.pone.0007384.g001
IBV Replicase in Pathogenicity
PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7384PCR using oligonucleotides BG56 and 93/100 to determine the
identity of the 39-UTR.
Serial passage of rBeauR-Rep-M41-Struct
Confluent monolayers of CK cells were used for serial passage
of rBeauR-Rep-M41-Struct 25 times. Briefly, cells were infected
with the rIBV and 24 h post-infection medium was collected,
diluted 1:10 and used to infect a new monolayer of CK cells. This
process was repeated until passage 25 (P25). Total RNA was
extracted from the P25 infected CK cells and RT-PCR was used to
generate a series of overlapping PCR products covering the
complete genome of the P25 rIBV. The RT-PCR products were
sequenced using a variety of oligonucleotides, derived from the
Beau-CK sequence [40]. Assembly of the sequences was
performed using Gap4 of the Staden Sequence Software Programs
[41].
Results
Generation of chimaeric rIBVs with the replicase gene
from Beaudette and the rest of the genome M41-CK
A full-length IBV-derived cDNA, within the vaccinia virus
genome, was generated by homologous recombination using the
TDS method and consisted of the replicase gene from the
apathogenic IBV strain Beau-R and the structural and accessory
genes plus the 39-UTR from the pathogenic M41 strain of IBV.
This was achieved using a Beau-R-based receiver sequence
consisting of the complete replicase gene, followed by the first
376 nt of the S gene fused to the N gene and 39-UTR (Fig. 1). The
donor sequence consisted of the last 1246 nt of the Beau-R
replicase gene fused to M41-CK-derived cDNA from the S gene to
the poly(A) tail (Fig. 1).
Following TDS, DNA was extracted from 20 rVVs, potentially
containing the chimaeric IBV full-length cDNA. Analysis by PCR,
using GPT specific primers to confirm the loss of the E. coli GPT
gene, on six of the rVV DNAs confirmed the loss of the GPT gene
following the second TDS recombination event (Fig. 1). The IBV
cDNAs within these six rVV DNAs were analysed (1) for the
presence of the M41-CK-derived 39-UTR sequence, which is
184 nt shorter than the Beau-R 39-UTR [42], (2) the junction
between the replicase and S gene using oligonucleotides BG40 and
BG134 and (3) for the presence of the M41-CK-derived M gene
using oligonucleotides BG52 (59-
24945GAATGGTGTTCTT-
TATTG
24962-39) and BG146 (59-
25549 TCTAACACTC-
TAAGTTGAG
25567-39); to confirm that the second TDS
recombination event had not resulted in generation of the starting
receiver sequence (Fig. 1). Two rVVs, rVV-BeauR-Rep-M41-
Struct-2 and rVV-BeauR-Rep-M41-Struct-12, that did contain
the M41-CK-derived 39-UTR and M gene were further screened
by spot sequence analysis of the IBV cDNA to confirm that the
region downstream of the Beau-R replicase gene had been
replaced with the corresponding sequence from M41-CK; the
sequences were as expected for the required chimaeric IBV
sequence.
Recovery of infectious rIBVs from the rVVs
Two infectious rIBVs, rBeauR-Rep-M41-Struct-2 and rBeauR-
Rep-M41-Struct-12, were recovered from DNA extracted from rVV-
BeauR-Rep-M41-Struct-2 and rVV-BeauR-Rep-M41-Struct-12, re-
spectively, using CK cells, previously infected with rFPV/T7, to
provide T7 RNA polymerase, and co-transfected with the rVV DNA
and pCi-Nuc [35]. The transfected CK cells (P0) were incubated until
they showed a cytopathic effect (CPE), the medium was filtered to
remove any rFPV/T7 and any potential rIBV passaged three times
more on CK cells (P3). Total RNA from the infected P3 CK cells was
extracted and analysed by RT-PCR and spot sequence analysis.
Sequence analysis showed that rBeauR-Rep-M41-Struct-12 contained
an extra adenosine nucleotide at position 25317 in a six base
polyadenosine repeat sequence within the M41 intergenic region (IGR)
between the end of the M gene and start of gene 5. Consequently only
rBeauR-Rep-M41-Struct-2 from the P3 CK cells was titrated in CK
cells and used for further characterisation. Sequence analysis of the
M41-CK-derived sequence in rBeauR-Rep-M41-Struct-2 revealed
three nucleotide changes when compared to the sequence in rVV-
BeauR-Rep-M41-Struct-2 (Table 1). The nucleotide changes resulted
in one amino acid change in the S protein, the other was a silent
mutation and a single amino acid change in the N gene. Comparison
of the sequence indicated that the changes arose during rescue or
during the first three passages of the rescued viruses.
Characterisation of the rIBV in vitro
The growth characteristics of rBeauR-Rep-M41-Struct-2 were
investigated and compared to Beau-R and M41-CK in vitro using
CK cells infected with 2610
5 PFU (MOI <0.1). The titres of the
progeny viruses were analysed over a 96 h post-infection period.
As can be seen from Fig. 2, Beau-R reached peak titres by 24 h
post-infection whereas M41-CK and rBeauR-Rep-M41-Struct-2
reached peak titres by 48 h post-infection. However, whereas
M41-CK reached a similar titre as Beau-R by 48 h post-infection,
the titre of rBeauR-Rep-M41-Struct-2 was approximately 1 log10
lower and remained lower over the rest of the time course.
Characterisation of the rIBV in vivo
Twelve one-day-old SPF chickens, in four groups, were
inoculated with 0.1 ml of 10
6 PFU/ml of rBeauR-Rep-M41-
Table 1. Nucleotide substitutions identified in the rIBVs when compared to the IBV sequence in rVV-BeauR-Rep-M41-Struct-2.
IBV gene
Genome
position
a
Nucleotide
change Codon change
Amino acid
substitution
Position in
protein
Occurrence of
substitution
S 20467 URC UUURCUU PheRLeu 34 P3RP25
20676 CRU AACRAAU Silent Asn 103 On rescue
22266 CRA GACRGAA AspRGlu 633 On rescue
5b 25815 URA UUURUAA PheRStop 30 P3RP25
25816 URA
N 26172 CRA AACRAAA AsnRLys 85 On rescue
abased on the sequence of IBV Beau-R accession No AJ311317.
doi:10.1371/journal.pone.0007384.t001
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(mock infection) by eye-drop and intranasally. The birds were
observed for clinical signs up to 11 days post-inoculation. At 4 and
7 days post-infection the tracheas of three randomly selected
chickens from each group were examined for ciliary activity and
presence of IBV. Observations for clinical signs, snicking,
wheezing and nasal discharge, of an IBV infection were carried
out daily on each group from three days post-infection. Only
chickens inoculated with M41-CK showed any clinical signs of an
IBV infection. As can be seen from figure 3, M41-CK induced
high rates of snicking, which peaked by day 5 post-inoculation,
whereas Beau-R and rBeauR-Rep-M41-Struct-2 induced a much
lower rate of snicking, similar to those observed for the mock-
inoculated chickens (Fig. 3A). Similarly, only chickens (11–16%)
inoculated with M41-CK showed any nasal discharge three, four
and six days post-inoculation (Fig. 3B). Again, wheezing was only
observed in chickens inoculated with M41-CK, in which 90% of
the infected chickens demonstrated wheezing by 7 days post-
inoculation (Fig. 3C). Analysis of the tracheas isolated from the
chickens showed that the mock, Beau-R and rBeauR-Rep-M41-
Struct-2 infected chickens had .95% ciliary activity whereas the
chickens inoculated with M41-CK showed 0% ciliary activity
(100% ciliostasis; Fig. 3D). In summary, our observations of the
parameters used to assess pathogenicity demonstrated that
rBeauR-Rep-M41-Struct-2 was not pathogenic and that it had
the characteristics associated with Beau-R rather than M41-CK.
Presence of IBV in the tracheas from the infected
chickens
In order to determine whether there was any virus in the
tracheas of the infected chickens, the epithelial cells were scraped
from the tracheas taken from three chickens from each group four
days post-infection and any virus present titrated in TOCs. The
average titre of M41-CK, isolated from the tracheas of the three
chickens, was 4.1 log10 CD50/ml, in contrast no detectable virus
was isolated from the tracheas taken from the chickens infected
with either Beau-R or rBeauR-Rep-M41-Struct-2. This result
indicated that if any virus was present in the tracheas of the
chickens infected with Beau-R or rBeauR-Rep-M41-Struct-2 the
amounts present were at least 4 log10 CD50/ml lower than the
M41-CK detected from the tracheas of the chickens infected with
M41-CK.
Analysis of IBV-RNA present in the tracheas of infected
chickens
Analysis of the tracheal epithelial cells isolated from the infected
chickens, for the presence of IBV by titration on TOCs, had
indicated that either there was no Beau-R or rBeauR-Rep-M41-
Struct-2 present or that the levels of both viruses were below
detection. Our previous results had shown that Beau-R was not
reliably detected in the tracheas of Beau-R in infected chickens
whereas M41-CK is detectable [26,43]. To check for the presence
of M41-CK-, Beau-R- or rBeauR-Rep-M41-Struct-2-derived
RNA in the tracheal epithelial cells from the infected chickens,
total RNA was isolated from the epithelial cells and analysed by
RT-PCR using oligonucleotides BG56 and 93/100, corresponding
to the 39-UTR of the IBV genomes. As can be seen from Fig. 4,
the tracheal epithelial cells isolated from chickens infected with
M41-CK were positive for the presence of M41-CK-derived RNA.
In contrast, no IBV-derived RNA was detected in the tracheal
epithelial cells of chickens infected with either Beau-R or rBeauR-
Rep-M41-Struct-2 supporting our virus isolation data. Further-
more, sequence analysis of the IBV-derived RT-PCR product
amplified from the tracheal epithelial cells of chickens infected
with M41-CK confirmed that it was derived from IBV M41-CK.
This was consistent with previous results suggesting that Beau-R
probably does not reach the tracheas of chickens infected by the
eye-drop and intranasal routes and that similarly rBeauR-Rep-
M41-Struct-2 did not appear to reach the epithelial cells of the
tracheas of infected chickens. A rIBV, BeauR-M41(S) [24], which
consisted of the Beau-R genome but with an M41-derived S gene,
had the tropism of M41 in vitro but the characteristics of Beau-R in
vivo indicating, together with our rBeauR-Rep-M41-Struct-2
result, that the inability of Beau-R-derived viruses to reach the
tracheas of infected chickens resides within the replicase gene.
Characterisation of the rIBV ex vivo
Infection of tracheal epithelial cells ex vivo is a method of
growing IBV strains that have not been adapted for growth either
in embryonated eggs or primary cell cultures and results in
cessation of ciliary activity (ciliostasis) of the epithelial cells.
Previous work demonstrated that our rIBVs, Beau-R and BeauR-
M41(S), caused ciliostasis of infected TOCs with concomitant
production of progeny virus [26]. Analysis of tracheal epithelial
cells from chickens infected with rIBV-BeauR-Rep-M41-Struct-2
had shown that there was no virus present. Therefore, we decided
to investigate the replication of rBeauR-Rep-M41-Struct-2, for
comparison with Beau-R and M41-CK, ex vivo in TOCs. Progeny
viruses in TOC medium taken from each group of infected TOCs
at the specific time points were titrated by plaque assay on CK
cells to investigate the growth kinetics of the three IBVs in TOCs.
As can be seen from Fig. 5 all three viruses replicated in the TOCs.
Although the viruses reached maximum titres by 24 h post-
infection, the titre of rBeauR-Rep-M41-Struct-2 was between 1-2
log10 units lower than the titres observed for M41-CK and Beau-
R, respectively, at this and most later time points. Interestingly,
although rBeauR-Rep-M41-Struct-2 replicated and produced
Figure 2. Growth profile of rIBV rBeauR-Rep-M41-Struct-2-P3
on CKCs. Monolayers of CKCs were infected with Beau-R, M41-CK or
rIBV rBeauR-Rep-M41-Struct-2-P3 at a MOI of 0.1 PFU/cell. After an
adsorption period of 1 h at 37uC, the cells were washed and incubated
for 96 h. At selected time points post-infection cell medium was
analysed for progeny virus by plaque titration assay on CKCs. Each
titration value is the mean of three replicates and standard error values
are shown as bars.
doi:10.1371/journal.pone.0007384.g002
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compared to the growth of Beau-R and M41-CK.
Serial passage of rBeauR-Rep-M41-Struct
Following rescue of rBeauR-Rep-M41-Struct-2 all growth
experiments were carried out using virus that had been passaged
three times (P3) in CK cells. We routinely use the P3-derived rIBVs
so that there is a lower probability that changes will have occurred
within the virus genome, as with other positive strand RNA viruses
multiple passage will result in changes in both nucleotides and
amino acids; for example the acquisition of the extra adenosine
residue in rBeauR-Rep-M41-Struct-12. The rIBV, rBeauR-Rep-
M41-Struct-2, showed slightly reduced growth properties when
compared with both parental viruses, Beau-R and M41-CK.
Surprisingly, although rBeauR-Rep-M41-Struct-2 grew in TOCs
it did not cause ciliostasis, which is induced by both parental
viruses. Due to the chimaeric nature of the rIBV the 59-UTR,
including the leader sequence, corresponds to Beau-R, with the 39-
UTR derived from M41-CK. There are known nucleotide
differences in these regions of the IBV genome between the two
viruses ([33,42]. This introduces the possibility that if the two
UTRs interact this could affect the growth properties of the
Figure 4. Detection of IBV-derived RNA by RT-PCR in tracheal
epithelial cells of infected chicks. Tracheas were removed 4 days
post-infection and epithelial cells were scraped from sections of the
tracheas and used for total RNA extraction using RNeasy kit (Qiagen).
The RT-PCR analyses were performed using oligonucleotides located at
the end of the N gene and at the end of the 39-UTR and analysed on 1%
agarose gels in which lane (M) contained 1 Kb Plus DNA Ladder marker;
and lanes 1–3 corresponded to tracheal epithelial cell extracts from
chicks infected with (1) Beau-R; (2) rBeauR-Rep-M41-Struct-2-P3 and (3)
M41-CK. An RT-PCR product of 483 nt was indicative of M41-derived
RNA (M41-CK and rBeauR-Rep-M41-Struct-2-P3) and a product of 667 nt
was indicative of Beau-R.
doi:10.1371/journal.pone.0007384.g004
Figure 3. Comparison of the pathogenicities of Beau-R, M41-CK and rBeauR-Rep-M41-Struct-2-P3. Four groups (n=12) of 1-day-old SPF
chicks were inoculated intranasally/eye drop with 0.1 ml of 10
6 PFU/ml of each virus. Mock-infected chicks were inoculated with 0.1 ml of medium.
Clinical signs were recorded from days 3 to 11 post-infection in which clinical signs were recorded for individual birds, apart for snicking where signs
were observed from a group. The clinical signs recorded were (A) snicking, (B) nasal discharge (mean of all birds), (C) wheezing (mean of all birds) and
(D) ciliary activity in tracheal rings (mean of 10 tracheal rings from three individual chicks per group).
doi:10.1371/journal.pone.0007384.g003
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difference between the 59-UTR and the conserved region of the
39-UTR, respectively, from Beau-R and M41-CK we decided to
serially passage rBeauR-Rep-M41-Struct-2 25 times on CK cells
to see whether this would result in a virus with a higher growth
rate and that could cause ciliostasis in TOCs and to determine in
the P25-derived virus whether this was a result of any nucleotide
substitutions in either of the UTRs or any other region of the
genome that may account for any potential change in phenotype.
The growth characteristics of rBeauR-Rep-M41-Struct-2-P25 were
initially examined in CK cells and compared to rBeauR-Rep-M41-
Struct-2-P3. As can be seen from Fig. 6A the peak titre of rBeauR-
Rep-M41-Struct-2 -P25 was higher, approximately 0.5 log10 unit,
than for rBeauR-Rep-M41-Struct-2 -P3 at 24 h post-infection and
remained higher throughout the time course. Subsequently, the
growth properties of rBeauR-Rep-M41-Struct-2-P25 were then
studied in TOCs and as can be seen from Fig. 6B rBeauR-Rep-
M41-Struct-2-P25 rIBV grew to a higher titre than rBeauR-Rep-
M41-Struct-2-P3,r e a c h i n ga1l o g 10 unit difference by 72 h post-
infection, although the two viruses had a similar titre by 96 h post-
infection. However, analysis of TOCs infected with rBeauR-Rep-
M41-Struct-2-P25 also showed that this virus did not cause ciliostasis.
In order to determine whether any nucleotide changes may
have been responsible for the observed phenotypic changes of the
P25 rIBV we decided to initially sequence the 59-and 39-UTRs of
rBeauR-Rep-M41-Struct-2-P25 for comparison to the correspond-
ing sequences of rBeauR-Rep-M41-Struct-2-P3 and the two
parental viruses Beau-R and M41-CK. No nucleotide changes
were found within the 59- and 39-UTR sequences of the rBeauR-
Rep-M41-Struct-2-P25 virus indicating that the change in growth
pattern was not due to one of the two UTRs changing to the other
parental sequence. As a result of this finding we sequenced the
complete rIBV rBeauR-Rep-M41-Struct-2-P25 genomic sequence
and identified only three other nucleotide changes (Table 1) in
addition to those identified within rBeauR-Rep-M41-Struct-2-P3.
These new nucleotide differences corresponded to a single amino
acid change in the S gene and two nucleotide changes within ORF
5b of gene 5 when comparing the M41-CK-derived sequences
within rBeauR-Rep-M41-Struct-2-P3 and rIBV rBeauR-Rep-
M41-Struct-2-P25 sequences; indicating that these changes arose
on further passage of rBeauR-Rep-M41-Struct-2-P3. The two
nucleotide changes within the ORF 5b sequence, nucleotides
25815 and 25816 (UURAA), resulted in the introduction of a
premature stop codon in ORF 5b and a modification of the N
gene transcription regulatory sequence (TRS) from UUCUUAA-
CAA to AACUUAACAA, the latter sequence being the more
predominant IBV TRS. Sequence analysis of the rBeauR-Rep-
M41-Struct-2 viruses between passages P3 and P25 (Fig. 7)
indicated that at P5, the AA mutation was more prominent than
the parental (UU) sequence and that in subsequent viruses, derived
from passages P10,P 15,P 20 and P25, the original parental sequence
gradually decreased and disappeared from detection.
Figure 5. Growth profile of rIBV rBeauR-Rep-M41-Struct-2-P3 in
TOCs. Groups of five TOCs were infected in triplicate with 0.5 ml of
5.4610
4 PFU/ml of Beau-R, M41-CK or rIBV rBeauR-Rep-M41-Struct-2-P3.
After 1 h at 37uC, the medium was removed and the TOCs were washed
3 times with PBS and incubated in 1 ml of medium for 96 hours. At
selected time points post-infection medium was analysed for progeny
virus by plaque titration assay on CKCs. Each titration value is the mean
of three replicates and standard error values are shown as bars.
doi:10.1371/journal.pone.0007384.g005
Figure 6. Growth profiles of the chimaeric rIBVs rBeauR-Rep-
M41-Struct-2-P3 and rBeauR-Rep-M41-Struct-2-P25 in CKCs and
TOCs. Following serial passage of rBeauR-Rep-M41-Struct-2-P3 in CKCs
the growth profiles of virus rBeauR-Rep-M41-Struct-2-P25 from passage
25 were compared to those of Beau-R and rBeauR-Rep-M41-Struct-2-P3
in (A) CKCs and (B) TOCs to determine whether passage resulted in an
altered growth profile. The viruses were analysed as described in Fig. 2
for CKCs and in Fig. 5 for TOCs.
doi:10.1371/journal.pone.0007384.g006
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Our previous work on the swapping of the S gene from the
avirulent Beaudette (Beau-R) strain of IBV with an S gene derived
from the pathogenic M41-CK isolate of IBV showed that although
the S gene was responsible for tropism it was not responsible for
virulence [24–26]. Although our results showed swapping of the S
gene did not result in virulence we could not rule out the fact that
other IBV structural (E, M and N) and accessory (3a, 3b, 5a and
5b) genes may also play a role and therefore be required for the
acquisition of virulence. We therefore decided to exchange the
region of the Beau-R genome from the end of the replicase gene to
the poly(A) tail with the corresponding sequence from M41-CK to
investigate whether exchange of the structural and accessory genes
was sufficient to confer pathogenicity to a resultant chimaeric
rIBV, rBeauR-Rep-M41-Struct. Such an approach would also
allow us to determine whether or not the replicase gene plays a
role in the pathogenicity of IBV. IBV Beaudette is a well known
apathogenic lab strain of IBV that was attenuated by multiple,
several hundred, passages in 11-day-old embryonic chicks [30],
therefore loss of virulence could have resulted in multiple changes
throughout the genome. IBV Beau-R is a molecular clone of
Beaudette-CK [35]) that is also avirulent in chickens [26].
The objective of this study was to determine whether replacing
the Beau-R structural and accessory genes with those from virulent
M41-CK would result in a rIBV that was virulent when compared
to Beau-R. We have used our IBV reverse genetics system
[24,25,35] to produce chimaeric IBV, rBeauR-Rep-M41-Struct,
consisting of the replicase gene from Beaudette (Beau-R) and the
S, 3a, 3b, E, M, 5a, 5b, N and the 39-UTR from M41-CK. The
M41-CK-derived structural and accessory gene sequence was
fused to the Beau-R replicase by homologous recombination using
the TDS method [25,37] and rIBVs were rescued in CKCs. The
M41-CK-derived region, in addition to the structural and
accessory genes in common with Beau-R, also contains an
untranslated region, the intergenic untranslated region (IGR),
between the M and gene 5, which is 305 nt in Beaudette and
350 nt in M41-CK. The M41-CK IGR, like some other strains of
IBV, contains a potential open reading frame (ORF) of 285 nt
potentially encoding a 94 amino acid product of 11 kD with the
initiation codon immediately downstream of the M gene stop
codon. A similar ORF has been identified at a similar position in
the genome of turkey coronavirus (TCoV) [5,6], the only TRS
identified for TCoV is 288 nt upstream of the potential ORF,
within the M gene, but with low identity to the TCoV canonical
TRS. No sg mRNA for this potential ORF has been identified in
TCoV or IBV, including M41-CK, infected cells. The lack of a sg
mRNA, the long distance between the initiation codon and a
potential TRS and the loss of the potential ORF, as a result of
several deletions, in some strains of IBV indicates that the ORF is
probably a pseudogene.
Two rIBVs, rBeauR-Rep-M41-Struct-2 and rBeauR-Rep-M41-
Struct-12, were rescued from the rVVs, rVV-BeauR-Rep-M41-
Struct-2 and rVV-BeauR-Rep-M41-Struct-12, respectively, and
analysed for the presence of the M41-CK-derived sequence.
Analysis of rBeauR-Rep-M41-Struct-12 identified an extra
adenosine nucleotide at position 25317 in a six base polyadenosine
repeat sequence within the potential 11.5 kD ORF in the M41-
CK IGR, which had the potential for inactivating this potential
gene product. To rule out the possibility that the loss of this
potential gene product could affect any pathogenicity of this virus
we decided to proceed with rBeauR-Rep-M41-Struct-2, which
had the correct sequence, for subsequent experiments.
We have characterised rBeauR-Rep-M41-Struct-2-P3 in vitro, ex
vivo and tested its pathogenicity in vivo using one-day-old- chickens.
The overall growth pattern of rBeauR-Rep-M41-Struct-2 in
CKCs was more similar to that of Beau-R (Fig. 2) except it grew
to a titre of about 1 log10 less throughout the growth cycle. The
main objective of this study was to determine whether swapping of
the structural and accessory genes would restore virulence. To this
effect we used rBeauR-Rep-M41-Struct-2 to infect one-day-old
chicks, and used clinical signs and measurement of the ciliary
activity of the epithelial cells lining the trachea of the infected
Figure 7. Acquisition of the premature stop codon identified in
ORF 5b following serial passage of rBeauR-Rep-M41-Struct-2-
P3. Sequence analysis of rBeauR-Rep-M41-Struct-2-P25 identified a di-
nucleotide substitution, UURAA, which resulted in a premature stop
codon in ORF 5b. The figure compares the sequence chromatograms
showing the acquisition of the stop codon in the virus genomes
following passage of rBeauR-Rep-M41-Struct-2-P3 (P3) through to
rBeauR-Rep-M41-Struct-2-P25 (P25). The line highlights the second
nucleotide of the pair, showing that at passage 5 the rBeauR-Rep-
M41-Struct-2 was a mixed population and that it appeared both
substitutions occurred simultaneously and that by P15 rBeauR-Rep-M41-
Struct-2 preferentially contained the substituted nucleotides.
doi:10.1371/journal.pone.0007384.g007
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clinical signs, snicking, wheezing and nasal discharge, associated
with an IBV infection were observed in the chickens infected with
either rBeauR-Rep-M41-Struct-2 or Beau-R; the latter as in
previous experiments did not show any clinical signs [26]. In
contrast, chickens infected with M41-CK did show clinical signs of
an IBV infection (Fig. 3); as shown previously [26]. These
observations demonstrated that rBeauR-Rep-M41-Struct-2 was
not pathogenic indicating that replacement of the structural and
accessory genes did not restore virulence.
Analysis of epithelial cells, removed from the tracheas of the
infected chickens, for the presence of infectious IBV using TOCs
failed to detect virus from chickens infected with either Beau-R or
rBeauR-Rep-M41-Struct-2. In contrast, epithelial cells from
chickens infected with M41-CK showed the presence of virus
with a titre of 4 log10 CD50 in TOCs, demonstrating that M41-CK
was present in the tracheas of the infected chickens. Analysis of the
epithelial cells for the presence of any IBV-derived RNA by RT-
PCR also indicated that no Beau-R or rBeauR-Rep-M41-Struct-2
was present or was below detection in the epithelial cells
examined; this was in contrast to the cells examined from chickens
infected with M41-CK, in which virus-derived RNA was detected
by RT-PCR (Fig. 4).
Subsequent analysis of rBeauR-Rep-M41-Struct-2 ex vivo using
TOCs surprisingly showed that the rIBV did not cause ciliostasis
when directly used to infect TOCs, in contrast to Beau-R and
M41-CK which caused ciliostasis. This observation raised the
possibility that the lack of ciliostasis and detection of rBeauR-Rep-
M41-Struct-2 in the tracheal epithelial cells of chickens infected by
the virus using TOCs for our pathogenicity experiments may have
been interpreted incorrectly as the read out for these tests was
ciliostasis. However, it should be noted no clinical signs were
observed nor was any rBeauR-Rep-M41-Struct-2-derived RNA
detected. Growth analysis of rBeauR-Rep-M41-Struct-2 in TOCs
showed that the lack of ciliostasis observed with rBeauR-Rep-
M41-Struct-2 was not due to the inability of the virus to replicate
in TOCs (Fig. 5). The rIBV rBeauR-Rep-M41-Struct-2 was able
to replicate in TOCs, though the amount of virus produced was
about 1 log10 less than for the growth of Beau-R and M41-CK,
somewhat analogous to the growth pattern observed for the virus
on CKCs.
IBV rBeauR-Rep-M41-Struct-2 consisted of the Beau-R
replicase and M41 structural and accessory genes and as a
consequence had a 59-UTR derived from Beau-R and a 39-UTR
from M41. There are known differences between IBV 39 UTRs, in
fact the M41-CK 39-UTR is 184 nt smaller than the Beau-R 39-
UTR, the remaining part of the M41-CK 39-UTR representing
the conserved region of the IBV 39-UTR and contains the
predicted RNA secondary structures believed to be involved in
replication [44]. There are 7 and 3 nucleotide differences between
the 59- and the conserved region of the IBV 39-UTRs, respectively,
of Beau-R and M41-CK ([33,42], raising the possibility that if the
two UTRs interact during replication their heterologous nature
could be responsible for the observed decrease in growth for
rBeauR-Rep-M41-Struct-2 in both CKCs and TOCs. Impair-
ment in growth on TOCs may also have been responsible for the
loss of ciliostasis. We hypothesised that an increase in growth
would be a selective advantage to the virus and therefore decided
to serially passage rBeauR-Rep-M41-Struct-2 25 times on CKCs
to see whether any adaption could result in a higher growth rate
and a virus that could cause ciliostasis in TOCs. For example, due
to the very few differences in the 59- and 39-UTRs, between the
two parental viruses, a nucleotide substitution in either UTR that
may result in a more homogenous interaction, as seen with either
parental virus, may result in an increase growth rate. Analysis of
the passaged virus, rBeauR-Rep-M41-Struct-2-P25, on CKCs and
TOCs showed an altered growth rate in comparison to rBeauR-
Rep-M41-Struct-2-P3 (Fig. 6). However, rBeauR-Rep-M41-
Struct-2-P25 still did not cause ciliostasis in TOCs. Sequence
analysis of the 59- and 39-UTRs of rBeauR-Rep-M41-Struct-2-P25
showed that there were no nucleotide substitutions within these
regions when compared to rBeauR-Rep-M41-Struct-2-P3, indi-
cating that the change in the growth characteristics was not
associated with changes in the UTRs. We therefore sequenced the
entire genome of rBeauR-Rep-M41-Struct-2-P25 for comparison
with the sequence in rVV-BeauR-Rep-M41-Struct, used for
generating rBeauR-Rep-M41-Struct-2-P3, in order to identify
any potential changes that may have been responsible for the
phenotypic change in growth. We identified three nucleotide
changes between the P3 and P25 viruses, one resulted in an amino
acid change, PheRLeu, in the S1 region of the S gene and two
adjacent nucleotides in the ORF-5b sequence that had two
potential effects, (1) the introduction of a premature stop codon in
ORF-5b and (2) modification the N gene TRS. These observations
indicate that the increase in growth associated with rBeauR-Rep-
M41-Struct-2-P25 could have arisen from the amino acid change
in the S protein, the loss of ORF-5b or a potential change in the
expression levels of sg mRNA 6, which is responsible for the
expression of the N protein. Overall, the main conclusion from our
results is the fact that rBeauR-Rep-M41-Struct-2 was non-
pathogenic; indicating that the loss of virulence associated with
Beaudette is not determined by the structural and the accessory
genes of IBV but resides within the replicase gene.
Our results demonstrating that the IBV replicase gene is a
determinant of pathogenicity differs from the conclusion by Navas-
Martin et al. [45] who reported that the differences in
pathogenicity between two strains of the murine coronavirus
mouse hepatitis virus (MHV), MHV-JHM and MHV-A59,
mapped to the MHV genome encoding the structural and
accessory genes downstream of the haemagglutinin esterase (HE)
gene. The replicase gene was interchangeable between the two
virus genomes but the differences in pathogenicities associated
with two viruses did not appear to correlate with the replicase
genes of the rMHVs generated. However, a major difference
between the two MHV isolates and the two IBV viruses we used
was that the two MHVs were pathogenic but demonstrated
different pathogenicities, neurovirulence and hepatitis, respective-
ly, whereas the difference between the two IBV isolates used in this
work was that one causes disease and the other does not. It is clear
from the MHV work that both replicase sequences are of a
‘‘virulent’’ phenotype and that the pathogenicity phenotype of the
recombinant viruses is associated with the structural and accessory
genes. In contrast our results demonstrated that loss of virulence
per se can be determined by some attenuating modification to one
or more of the coronavirus replicase components. Recent work
involving the attenuation of a nephropathogenic strain of IBV by
serial passage in embryonated chicken eggs, reported that the virus
became fully attenuated by passage P110 [46]. Sequence analysis of
the 39-7 kb (S gene to poly(A) tail) region of the genome from the
P110 virus identified several amino acid substitutions and a 109 nt
deletion within the 39 UTR when compared to P0 virus. The
authors reported that the changes identified were potentially
responsible for attenuation; they did not report any changes within
the replicase gene of the P110 virus and indicated that other
changes, apart from those identified in the 39-7 kb region, within
the genome may also be involved in attenuation. Other workers
attenuated the virulent Ark DPI 11 strain of IBV following 101
passages in embryonated eggs (Ark DPI 101) and compared the
IBV Replicase in Pathogenicity
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changes corresponding to 17 amino acid changes [47]. The
nucleotide changes resulted in eight amino acid changes in Nsp2
(1), Nsp3 (3), Nsp6 (2), Nsp10 (1) and Nsp13 (1) of the replicase
protein, eight amino acid changes in the S protein and one amino
acid in ORF 5a and the N protein. The authors were unable to
confirm which amino acid changes were responsible for loss of
pathogenicity. Taking into consideration our results that loss of
virulence associated with the Beaudette strain resides in the
replicase and the results of Ammayappan et al. [47], it is possible
that very few amino acid substitutions within the replicase gene
can result in attenuation following serial passage in embryonated
eggs.
The replicase gene of IBV encodes 15 Nsps, some of them with
known enzymatic functions [48]. How these proteins function in
the context of pathogenesis is still not well understood, however,
some of the Nsps for other coronaviruses have been linked to loss
of virulence. For example, the loss of Nsp1 from MHV did not
affect replication in tissue culture but severely attenuated the
rMHV in vivo [49]; inactivation of the MHV ADP-ribose-
10phosphatase activity in Nsp3 caused a reduction in virus
replication in the livers of infected mice but did not induce liver
disease [50] and a single amino acid change in the MHV Nsp14
did not alter the replication of the rMHV in tissue culture but
resulted in attenuation in mice [51].
Our previous spike swapping results demonstrated that
introduction of an S protein from a virulent isolate of IBV did
not confer virulence on Beau-R indicating that loss of virulence
was not receptor-mediated. Results from work described here has
shown that replacing all the Beaudette structural and accessory
proteins with those from a virulent isolate of IBV did not restore
virulence. Generation of the rIBV produced in this work can either
be viewed as replacing the structural and accessory genes of an
avirulent virus with those of a virulent virus or replacing the
replicase gene of a virulent isolate (M41-CK) with one from an
avirulent virus (Beau-R). In either scenario our results indicate that
loss of virulence associated with IBV Beaudette resides within one
or more of the 15 IBV replicase proteins comprising the IBV
replicase gene.
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